A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry
Backgound: Pharmaceutical subsidy schemes are under increasing pressure to evaluate the cost effectiveness of new highly specialised and orphan drugs for universal subsidy. In the absence of longer-term outcome data, drug sponsors often present modelled data, which can carry a significant level of u...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2008
|
| Online Access: | http://hdl.handle.net/20.500.11937/8622 |